Loading stock data…
Amylyx Pharmaceuticals, Inc. (AMLX)
$34.10+0.14 (+0.41%)
Pre-Market$33.91-0.19 (-0.56%)· Last close Sep 4
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amylyx Pharmaceuticals, Inc. in the Healthcare sector is trading at $34.10 with a market capitalization of $3.8B. Wall Street consensus targets $42.36 (11 analysts), implying a +24.2% move over the next 12 months. The stock is currently 17% below its 52-week high of $41.14, remaining 102.1% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +24.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$43.78M↓ | -$36.60M↓ | -$36.03M↑ | -$42.86M↓ | -$37.80M |
| Net Income | -$41.28M↓ | -$33.00M↑ | -$34.39M↑ | -$41.44M↓ | -$35.91M |
Peer Comparison
JNJUNHPFE
Fundamentals
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.59%
Volume
Today's trading volume
885,518
Recent News
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx looks promising, but a pullback would improve the opportunity.
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Eli Lilly is currently leading the GLP-1 market, but Amylyx is seeing strong results from its GLP-1 drug candidate.
Oracle Stock And 2 High Growth Picks Backed By Rising Credit Demand
Eurozone private sector credit growth is gaining pace, which points to households and businesses feeling more confident about borrowing for spending and investment. That kind of backdrop can support companies with healthy balance sheets and room to grow earnings. The Healthy high growth potential screener filters for exactly that mix. This article highlights 3 stocks from the screener that fit this theme and merit a closer look. The stocks covered in the article below are just a small sample,...
Oracle Stock And 2 Growth Picks With Strong Earnings Potential
Germany’s Ifo index has reached a one year high, which hints at a more confident backdrop for companies planning to grow earnings rather than just defend margins. That creates an interesting setting for investors looking for earnings momentum combined with balance sheet discipline. This article examines three stocks from the Healthy high growth potential screener and explains why this blend of growth and financial strength may be appealing at this point. The stocks covered below are only a...
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
The biotech delivered excellent news from the laboratory.